# SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

Study · id `cardio:ct-nct06442280` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06442280](<https://clinicaltrials.gov/study/NCT06442280>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06442280

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 544 participants.

## Technical summary

Registry record NCT06442280. Randomized; single masking; primary purpose treatment. Start 2024-06 (anticipated); primary completion 2026-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 544 participants (planned count; ClinicalTrials.gov record NCT06442280, source copy `cardio:ctgov-nct06442280-2024-06-06`, retrieved 2026-10-26)
- Planned start: 2024-06 (anticipated) (ClinicalTrials.gov record NCT06442280, source copy `cardio:ctgov-nct06442280-2024-06-06`, retrieved 2026-10-26)
- Primary completion: 2026-01-31 (anticipated) (ClinicalTrials.gov record NCT06442280, source copy `cardio:ctgov-nct06442280-2024-06-06`, retrieved 2026-10-26)
- Completion: 2026-03-30 (anticipated) (ClinicalTrials.gov record NCT06442280, source copy `cardio:ctgov-nct06442280-2024-06-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06442280-2024-06-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF
- Acronym: DAPA-TONIC
- Condition: Heart Failure Acute
- Condition: Diabetes Type 2
- Condition: Heart Failure With Reduced Ejection Fraction
- Condition: Heart Failure With Preserved Ejection Fraction
- Intervention (Drug): Dapagliflozin tablet
- Intervention (Drug): Hypertonic Saline Solution, 1 Ml
- Intervention (Drug): Furosemide Injection
- Lead sponsor: University of Palermo
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Palermo (`cardio:org-university-of-palermo`)

## Provenance

Content hash: 170fe74980b543d0a34b0d9774fd834f968e9d1e712742350cb1dce51c258d5a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
